NCT00417274

An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer

Completed Phase 2 Results posted Last updated 6 March 2013

What this trial tests

Phase 2 trial testing Quinacrine in Prostatic Cancer in 31 participants. Completed in 1 May 2008.

Timeline

1 December 2006

Primary endpoint
1 May 2008

1 May 2008

Quick facts

Lead sponsor	Cleveland BioLabs
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	1 December 2006
Primary completion	1 May 2008
Estimated completion	1 May 2008

Drugs / interventions tested

• Quinacrine — full drug profile →

Conditions studied

• Prostatic Cancer — all drugs for Prostatic Cancer →

Sponsor

Cleveland BioLabs

Who can join

18 and older, male only, with Prostatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Efficacy of Quinacrine, Based on Prostate Specific Antigen (PSA) Response in Patients With Androgen-independent Metastatic Prostate Cancer
  Time frame: End of treatment
  Patients who achieved a complete response (CR) or a partial response (PR) to therapy were allowed to continue to receive treatment until disease progression or unacceptable toxicity occurred, until the patient discontinued treatment for another reason, or for a total of 6 months. Patients who continued to show a CR or PR or who maintained stable disease (SD) after 6 months of therapy were to be al

Sponsor's own description

The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.
   Ehsanian R, Van Waes C, Feller SM. · · 2011 · cited 98× · PMID 21569639 · DOI 10.1186/1478-811x-9-13
2. Modulating cancer cell survival by targeting intracellular cholesterol transport.
   Kuzu OF, Gowda R, Noory MA, Robertson GP. · · 2017 · cited 48× · PMID 28697173 · DOI 10.1038/bjc.2017.200
3. Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
   Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006
4. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
   Salas Rojas M, Silva Garcia R, Bini E, Pérez de la Cruz V, et al · · 2021 · cited 17× · PMID 33477376 · DOI 10.3390/v13010121
5. Co-targeting of lysosome and mitophagy in cancer stem cells with chloroquine analogues and antibiotics.
   Al-Bari MAA. · · 2020 · cited 16× · PMID 32935427 · DOI 10.1111/jcmm.15879
6. Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma.
   Bryant J, Batis N, Franke AC, Clancey G, et al · · 2019 · cited 10× · PMID 31497252 · DOI 10.18632/oncotarget.27156
7. Quinacrine, an Old Drug with Potentially usefull in the Treatment for COVID-19.
   Pineda B. · · 2021 · cited 1× · PMID 34154830 · DOI 10.1016/j.arcmed.2021.06.002
8. Repositioning Quinacrine Toward Treatment of Ovarian Cancer by Rational Combination With TRAIL.
   Liang R, Yao Y, Wang G, Yue E, et al · · 2020 · cited 1× · PMID 32766144 · DOI 10.3389/fonc.2020.01118